OCT has been awarded with an ophthalmological study by a French company

This is an international, multicentre, randomized, investigator-masked phase III study conducted in 2 treatment arms.

The primary objective of the study is to demonstrate the non-inferiority of the investigational eye drops compared to the reference product in ocular hypertensive or glaucomatous patients. The treatment duration will not exceed 3 months. It is planned to randomize up to 400 patients in 100 investigational sites located in 13 countries.

In this trial, OCT is responsible for selection and monitoring of five investigational sites in Ukraine, regulatory support, project management, drug import and distribution activities, translation of study-related documents.